RE:IRENE StudyIRENE is a Phase 2 investigator sponsored trial in TNBC involving pelareorep + (Incyte's) Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1) and a recorded primary completion date as January 30, 2024.
https://classic.clinicaltrials.gov/ct2/show/NCT04445844